Natural killer (NK) cells have been shown to have important functions in anti-tumor responses and therefore have been used as adoptive immunotherapy for cancer
Natural killer (NK) cells have been shown to have important functions in anti-tumor responses and therefore have been used as adoptive immunotherapy for cancer. CELL PRODUCTS Remote manufacturing of cell therapy products in centralized facilities is likely to be the norm in the future. As a PACT manufacturing facility, we have shipped NK cell products to the clinical site located in another state, and we have had to optimize conditions for overnight cell shipment. We first explored the possibility of shipping expanded NK cells cryopreserved in 10% DMSO, 40% HBSS and 40% human serum albumin ICA-121431 solution (containing 25% HSA). Notably, greater than 70% of the cells were viable within several hours of thaw, they were not cytotoxic. While their potency could be regained after overnight culture in IL-2, their viability dropped significantly (Fig. 5). Further, thawed NK cells did not expand in patients.5 Therefore, we explored the possibility of shipping ICA-121431 NK cells formulated for infusion at 1107 cells mL-1 in infusion buffer Buminate 5% (Baxter, Deerfield, IL) at room temperature and at 4C15C (on ?20C frozen insulated ice packs). Shipping formulated cells allows infusion upon arrival at the clinical site. In our trial, the clinical site counts the cells, removes cells in excess of the infusion dose, and performs additional sterility testing. We found that expanded NK cells shipped both at RT and on ice in Fenwal transfer packs retained greater than 90% viability and potency within 48 hours after formulation ICA-121431 without cell loss (Fig. 5 and Table 3). We finally chose to ship the cells on ice packs because the temperature was more stable (temperature fluctuated from 8 to 11C) during shipping on ice packs compared to room temperature conditions, which fluctuated from 5 to 21C. Open up in another window FIG. 5 Characterization of fresh and cryo-preserved extended NK cell products. (A, B) Extended and cryopreserved NK cells stay practical within hours post thaw; nevertheless, eliminating K562 cells usually do not. Cryopreserved cells regain their strength after over night incubation, however, reduce their viability. Newly developed NK cells (N=3) stay potent after delivery at ambient temps or on freezing ice packages (C). TABLE 3 Viability of NK cells (N=3) 48 hours post-formulation at 1107 cell mL-1 in 5% human being serum albumin (HSA) enlargement allows lower infusion cell dosages, and the decision of supplementary cytokines needs more explanation. Research are necessary ICA-121431 to distinguish the ultimate way to cryopreserve the NK cells in order that adequate cells could be expanded at onetime to permit multiple infusions. This might facilitate third-party applications also. Long term medical research with NK cells will likely include genetic modifications to enhance and expand specificity and function, while combinatorial treatments with T cells and small molecules should potentiate their function and take advantage of their ability to recruit and activate the adaptive immune response. All studies should include detailed patient immune monitoring post infusion to measure expansion, cytokine secretion and to identify epitope-spreading that could be a marker of activation of adaptive responses. Acknowledgments We are thankful to all members of the cell processing and vector production RNF49 facilities and the flow cytometry laboratory of Center for Cell and Gene Therapy for their help with this work. This work was supported in part by NIH-NHLBI- N01 HB37163, NHLBI-1U54 “type”:”entrez-nucleotide”,”attrs”:”text”:”HL081007″,”term_id”:”1051651415″,”term_text”:”HL081007″HL081007 and NIH-NCI PO1 CA94234, NIH-NCI PO1 CA55819, and NIHNCI RO1 “type”:”entrez-nucleotide”,”attrs”:”text”:”CA134522″,”term_id”:”35021619″,”term_text”:”CA134522″CA134522. ABBREVIATIONS AMLacute myeloid leukemiaB-ALLacute B-cell lymphoblastic leukemiaC-ALLcommon acute lymphoblastoid leukemiaH-SCThematopoietic stem cell transplantILinterleukinN/Anot applicableNK cellnatural killerPBMCperipheral blood mononuclear cellsSCGMstem-cell growth medium.
